PRTK Paratek Pharmaceuticals Inc.

+0.19  (+3%)
Previous Close 6.97
Open 7
Price To Book 4
Market Cap 231157750
Shares 32,284,602
Volume 176,961
Short Ratio
Av. Daily Volume 372,167

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approved November 23, 2011.
Phase 3 data released July 17, 2017 - all endpoints met.
Omadacycline - oral
Acute bacterial skin and skin structure infections (ABSSSI)
FDA Approval announced October 2, 2018.
Acute bacterial skin and skin structure infections (ABSSSI)
FDA Approval announced October 2, 2018.
Community-acquired bacterial pneumonia (CABP)
FDA Approval announced October 2, 2018.
Severe acne vulgaris
Phase 2 data due 2H 2019.
Urinary tract infections
Phase 2 dosing announced November 27, 2018 with data due 2H 2019.
Complicated urinary tract infections (cUTI)

Latest News

  1. Will Paratek Pharmaceuticals (PRTK) Report Negative Earnings Next Week? What You Should Know
  2. Paratek Pharmaceuticals to Present at the 8th Annual SVB Leerink Global Healthcare Conference
  3. Paratek Pharmaceuticals to Report Fourth Quarter and Full Year 2018 Financial Results on February 27, 2019
  4. New England Journal of Medicine Publishes Results from Pivotal Phase 3 Studies of Paratek’s NUZYRA™ (Omadacycline) For Pneumonia and Skin Infections
  5. The Daily Biotech Pulse: Paratek Launches Antibiotic In US, Eli Lilly Earnings, Catabasis Offering
  6. Paratek Pharmaceuticals Launches NUZYRA™ (Omadacycline) in the United States
  7. Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
  8. What You Must Know About Paratek Pharmaceuticals, Inc.’s (NASDAQ:PRTK) Beta Value
  9. Antimicrobials Working Group Announces Updates to Leadership Team
  10. Arbiter Partners Capital Management’s Returns, AUM and Holdings
  11. Hedge Funds Are Selling Paratek Pharmaceuticals Inc (PRTK)
  12. Analysis: Positioning to Benefit within Paratek Pharmaceuticals, Chesapeake Utilities, Eros International, Sunoco LP, Delek Logistics Partners, and Johnson Controls International plc — Research Highlights Growth, Revenue, and Consolidated Results
  13. Paratek Pharmaceuticals Files Two Patent Term Extensions in the United States; Expects NUZYRA™ Patent Protection Exclusivity Until at Least October 2030
  14. Paratek Pharmaceuticals Doses First Patient in Phase 2 Clinical Trial of Omadacycline in Acute Pyelonephritis, a Common Subset of Complicated Urinary Tract Infections
  15. Edited Transcript of PRTK earnings conference call or presentation 6-Nov-18 9:30pm GMT
  16. Do Institutions Own Paratek Pharmaceuticals Inc (NASDAQ:PRTK) Shares?
  17. Paratek Pharmaceuticals (PRTK) Reports Q3 Loss, Misses Revenue Estimates
  18. Paratek: 3Q Earnings Snapshot